Xencor (XNCR) Projected to Post Earnings on Tuesday

Xencor (NASDAQ:XNCR) is expected to announce its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.81) per share and revenue of $17.14 million for the quarter.

Xencor Stock Down 0.3 %

XNCR opened at $15.74 on Monday. Xencor has a 1-year low of $15.31 and a 1-year high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -4.92 and a beta of 0.70. The business has a 50 day moving average of $20.38 and a 200-day moving average of $20.74.

Insider Activity

In related news, Director Alan Bruce Montgomery sold 13,301 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $27.03, for a total value of $359,526.03. Following the transaction, the director now owns 9,140 shares in the company, valued at $247,054.20. This trade represents a 59.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.23% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on XNCR shares. Wells Fargo & Company initiated coverage on Xencor in a research report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 price objective for the company. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their target price for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. Wedbush restated an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Finally, JPMorgan Chase & Co. increased their price objective on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Xencor has an average rating of “Buy” and an average price target of $34.88.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.